A New Paradigm in Drug Development - The mission of Bio-Path is to make its neutral lipid delivery the standard delivery technology for antisense therapeutics in the pharmaceutical industry.
Liposomal Grb-2 Clinical Trial

Bio-Path completed six cohorts of the Phase I clinical trial evaluating Liposomal Grb-2 in blood cancers. The drug’s safety profile continues to be favorable with no treatment-related serious adverse events reported and data suggests possible anti-leukemia activity. A maximum tolerated dose has yet to be reached. The clinical trial is being conducted at the MD Anderson Cancer Center.

The Company expects to start its Phase II program by the end of 2014, which will include three Phase II clinical trials of Liposomal Grb-2 salvage therapy in combination with frontline therapy in three different leukemia disease types: AML, CML and MDS.

Latest News

Oct 16, 2014
NASDAQ Release: Bio-Path Holdings, Inc. to Ring The NASDAQ Stock Market Closing Bell (Friday, Oct. 17, 2014 at 3:45 - 4:00 PM Eastern Time)

Oct 7, 2014
Bio-Path Holdings Successfully Completes Cohort 6 of Phase I Clinical Trial Evaluating Liposomal Grb-2 in Blood Cancers

Sep 30, 2014
Bio-Path Holdings to Present at the 13th Annual BIO Investor Forum

Link to Webcast

Aug 18, 2014
Bio-Path Holdings Reports Second Quarter 2014 Operational and Financial Results

June 30, 2014
Bio-Path Holdings Added to Russell Global, Russell 3000® and Russell Microcap® Indexes